A fresh Form 4 filing shows Carl L. Gordon, a director of BlossomHill Therapeutics, Inc. (BLSM), purchased 625,000 shares of the company on the open market on August 10, 2026. The transaction, priced at $16.00 per share, totaled $10,000,000.00 — a purchase made with the insider’s own funds rather than acquired through options or other compensation-related awards.
Following the transaction, Gordon’s stake stands at 2,714,279 shares, which the filing indicates are held indirectly, likely through a trust or affiliated entity rather than in his own name. That distinction is common for directors and executives who manage large equity positions through investment vehicles for tax or estate-planning purposes, though the economic exposure to BLSM’s share price remains the same.
A Notable Coincidence in Timing
What makes this filing particularly interesting is its timing: it lands on the same date as another significant insider purchase at BlossomHill. As detailed in our earlier report, BLSM Insider Buy: OrbiMed Advisors Spends $10M on Shares, a separate $10 million open-market purchase was disclosed for the same day. Two insiders committing identical dollar amounts on the same date is the kind of clustering that tends to catch the attention of market watchers who track Form 4 filings closely.
Academic research on insider trading patterns has long noted that clustered buying — multiple insiders purchasing shares around the same time — can carry more statistical signal than a single isolated transaction. Studies on open-market insider purchases have found a correlation between such clustering and subsequent stock performance, though the relationship is probabilistic at best and far from a guarantee for any individual company or situation.
This filing is a routine disclosure required under SEC rules whenever a company insider — defined as an officer, director, or holder of more than 10% of shares — buys or sells stock. It offers no direct insight into BlossomHill’s business operations, clinical pipeline, or financial condition, and it should not be read as commentary on the company’s prospects. It simply documents that a sitting director chose to increase his economic exposure to the company at a specific price point on a specific date.
Readers interested in tracking how this position evolves, or in reviewing the full transaction history for BlossomHill Therapeutics insiders, can consult the underlying SEC filing for additional detail beyond what is summarized here.
→ See all BLSM coverage on WhoIsBuyingNow
Source: original SEC Form 4 filing.